A high-powered drug combo didn't make the grade in a new lung cancer trial. Combining Genentech's Avastin and OSI Pharmaceuticals' Tarceva didn't boost survival for patients who had not responded to chemotherapy, failing the trial's primary endpoint. Release [1] | Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/genentech-osi-pharmaceuticals-announce-topline-results-phase-iii-study-evaluating-com
[2] http://www.forbes.com/feeds/ap/2008/10/06/ap5512494.html